Abbott Laboratories (ABTCL.SN)
| Previous close | 108,200.00 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 25,998.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health
The global healthcare company Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative. Eight community health centers have been selected to receive funding, expert guidance and training to design and test new solutions to help advance nutrition and improve care in their communities.
- PR Newswire
Abbott Declares 402nd Consecutive Quarterly Dividend
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
- PR Newswire
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and welln
